

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Strategic Trading Analysis

Based on the provided Stock Detailed Analysis Report for CIPLA.NS (dated 2026-02-14), here is my assessment as a Positional Equity Trader.

Step 1: Audit the Data

● Data Present:

- **Price Structure:** Daily and Weekly charts, Candlestick classification.
- **Trend Indicators:** EMA (20, 50, 200), Supertrend (1W, 1D, 15m), MACD.
- **Momentum/Volatility:** RSI, Bollinger Bands, Volatility Squeeze.
- **Relative Strength:** RS Score, RS Ratio vs. Benchmark (^CNXPHARMA).
- **Fundamentals:** Revenue/EPS growth trends (Long-term & Short-term).

● Data Missing:

- **Broader Market Context:** No correlation data with the primary index (Nifty 50) to gauge general market sentiment.
- **Specific News Flow:** While earnings numbers are present (Net Income down), the specific *catalyst* or management commentary causing the drop is not detailed.
- **Confidence Level: High.** The technical report provides a comprehensive multi-timeframe view sufficient for a technical trade decision.

Step 2: Analyze the Setup

● Trend Direction: **Bearish (Strong Downtrend).**

- The stock is trading below all key EMAs (20, 50, 200).
- The 20 EMA (1355) is below the 50 EMA (1411), which is below the 200 EMA (1477)-a classic bearish alignment.
- The Daily Supertrend is in a "Sell" mode with resistance at 1403.

● Momentum: **Weak/Oversold.**

- RSI is at 34.97. While oversold, it has not yet confirmed a bullish divergence with a price reversal.
- MACD histogram is slightly positive, but the report notes momentum is "Weakening."

● Fundamental Headwinds:

- Short-term fundamentals are deteriorating significantly. Recent Quarterly Net Income is down **-47.92%** and Revenue growth is effectively flat (1.84%). This fundamental weakness validates the technical downtrend.

● Relative Strength:

- RS Score is 44.7/100. The stock is underperforming its sector (^CNXPHARMA), indicated by the RS line making new lows (Page 5). We generally avoid buying laggards in a positional strategy.

Conclusion: The stock is currently a "falling knife." While selling exhaustion was signaled on volume (Feb 2nd), price action has failed to follow through. The stock is currently rejected by the lower-middle Bollinger Band region.

Step 3: Formulate the Recommendation

Recommendation: NO

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Reasoning: Entering now violates the primary rule of intermediate-term trading: **Trend Alignment**. Buying now is "bottom fishing" against a strong downtrend and deteriorating earnings. The probability of the stock testing the 1280-1300 support zone again is higher than a V-shaped recovery.

However, given the oversold conditions, a "Mean Reversion" trade back to the 200 EMA is possible *if* the immediate selling pressure abates.

Conditional Plan (for a Reversal Setup):

We require confirmation of strength before risking capital.

- **Condition to Buy:** The stock must register a **Daily Close above the 20 EMA (currently ~1356)**. Ideally, wait for the Daily Supertrend to flip to Buy (requires a move >1403), but an aggressive entry can be taken on the EMA reclaim.
- **Entry Price: INR 1,365** (Allowing a buffer above the 20 EMA to avoid false breakouts).
- **Stop Loss: INR 1,280** (Hard stop below the recent swing low and lower Bollinger Band).
- **Take Profit: INR 1,475** (Just below the 200 EMA and previous breakdown levels).
 - *Risk/Reward Ratio:* ~1.3 : 1 (Acceptable for a counter-trend trade, but keeps upside within your 5-15% target range).

Candlestick Classification Analysis

Based on the **Candlestick Classification System** outlined in the report and the visual data from **Page 21 (Chart)** and **Page 20 (Summary)**, here is my analysis as a seasoned Price Action Trader.

Current Market State: Indecision (No Control)

Latest Classification: No Control (0) **10-Day Trend Score:** 0.00

The market for CIPLA.NS has shifted from a phase of high-conviction selling into a phase of equilibrium. The "Seller Strong Control" candles that dominated the chart in late January 2026 have dissipated, replaced by a series of grey, small-bodied candles.

Detailed Price Action Analysis (Page 21)

1. The Preceding Move: Institutional Dumping (Seller Strong Control)

Looking at the chart in late January (the large red candles with massive volume bars at the bottom):* **Body Logic:** These candles had large bearish bodies (>1.5 ATR), closing near their lows.* **Volume Logic:** The volume bars were significantly higher than the average line. According to your algorithm, **High Volume (>1.3x avg)** acts as a multiplier. This confirmed that institutions were exiting, locking in a "Seller Strong Control (-2)" classification.* **Result:** This created a "Waterfall" drop from ~1400 down to the 1300 levels.

2. The Current Setup: The "No Control" Zone

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

The most recent cluster of candles (far right of the chart) are predominantly **Grey (No Control)** with some intermittent **Light Red (Seller Control)**.* **Body Analysis:** The bodies are small (<0.5 ATR). This indicates that neither buyers nor sellers have the conviction to move the price significantly from the open by the end of the day.* **Wick Analysis:** We are seeing **long lower wicks** appearing on recent candles near the 1280-1300 zone. * *Algorithm Interpretation:* A long lower wick triggers a **bullish adjustment**. Even if the body is red, the wick signifies that sellers tried to push lower, but buyers stepped in to defend the price. This "rejection" prevents the score from sliding into "Seller Strong Control."* **Volume Analysis:** The volume has tapered off significantly compared to the panic selling in January. * *Algorithm Interpretation:* **Low Volume (<0.8x avg)** acts as a weakener (multiplier 0.6). Even if a candle looks bearish, the lack of volume participation downgrades the signal from "Seller Control" to "No Control."

Future Price Prediction

Based on the Candlestick Classification logic, the stock is at a **critical pivot point**.

The Verdict: Neutral with a **Bearish Bias (Wait for Breakout)**

The Trend Score of 0 . 00 indicates a pause in momentum, not necessarily a reversal. In candlestick theory, a "No Control" consolidation pattern within a strong downtrend (see Page 6, "Strong **Downtrend**") often acts as a **Bear Flag** (a rest period before continuing down) unless proven otherwise.

Scenario A: The Bearish Continuation (Most Likely)* Signal to Watch: A candle classified as **Seller Control (-1)** or **Seller Strong Control (-2)**.* **Logic:** If price closes below the recent wick support (~1280) with a body size >0.8 ATR and increasing volume, the "No Control" phase has ended in favor of sellers.* **Target:** New lows below 1280.

Scenario B: The Bullish Reversal (Buying Opportunity)* Signal to Watch: We need a **Buyer Strong Control (+2)** candle.* **Logic:** Currently, we only have "No Control." To turn this ship around, we need a candle with a Large **Bullish Body** (>1.5 ATR) that closes near the high, accompanied by High Volume (>1.3x). This would confirm that the "lower wicks" were indeed accumulation and not just short covering.* **Prediction:** Until a **+2** candle appears, the upside is capped at previous resistance (likely near the 1400 breakdown zone).

Trader's Conclusion: Do not buy yet. The "No Control" status means the bleeding has stopped, but healing hasn't begun. The market is absorbing the recent supply. Wait for a **Buyer Control (+1)** or **Buyer Strong Control (+2)** candle to confirm that the 1300 level is a verified floor. If the next significant classification is Red (-1 or -2), the downtrend resumes immediately.

News & Analyst Targets

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

As of February 14, 2026, here is the latest research and information on Cipla Ltd.

1) Latest News for CIPLA This Week

- **USFDA Observations at InvaGen (Negative):** In a regulatory filing this week (approx. Feb 10-13), Cipla disclosed that the **USFDA issued 2 observations** (Form 483) to its wholly-owned subsidiary, **InvaGen Pharmaceuticals**, in Hauppauge, New York. The inspection was a Pre-Approval Inspection (PAI) conducted from February 2-9, 2026. Cipla has stated it will address these observations comprehensively.
- **Stock Trading Near 52-Week Lows:** Following a series of negative regulatory news and weak Q3 earnings, Cipla's stock has been under pressure, trading in the **INR 1,315 - INR 1,340** range, which is close to its 52-week low.
- **GST Inspection Concluded:** A recent inspection by the GST department in Maharashtra concluded with **no material impact** on the company's financials or operations.

2) Brokerage Upgrades & Downgrades

The sentiment from the brokerage community has turned largely **cautious to bearish** in late January and early February 2026, primarily due to supply disruptions and weak earnings.

Downgrades:

- **Morgan Stanley** maintained an "**Underweight**" rating and cut its target to **INR 1,292**, citing supply disruptions for *Lanreotide* and the phase-out of *Revlimid* generics as key risks to FY27 earnings.
- **Jefferies** downgraded the stock to "**Underperform**" with a target of **INR 1,170**, the lowest on the street, highlighting that the current valuation does not fully price in the US sales headwinds.
- **Nuvama** downgraded the stock to "**Reduce**" with a target of **INR 1,360**, driven by concerns over margin compression and the Lanreotide stoppage.
- **BOB Capital Markets** downgraded Cipla to "**Hold**" with a target of **INR 1,394** following the disappointing Q3 results.

Maintained/Positive:

- **Nomura** remains a contrarian "**Buy**", maintaining a target of **INR 1,770**. They believe the negatives (including the Lanreotide issue) are already priced in and expect a recovery in the medium term.

3) Other News Impacting CIPLA (Direct & Indirect)

- **Lanreotide Supply Disruption (Major Indirect Impact):** A key partner for Cipla, **Pharmathen International** (based in Greece), recently received **9 USFDA observations** and paused production of *Lanreotide* (a key cancer drug and revenue driver for Cipla in the US). This is expected to significantly impact Cipla's US revenue for Q4 FY26 and H1 FY27, as supply will be constrained until remediation is complete.
- **Q3 FY26 Earnings Fallout:** The market is still digesting Cipla's **Q3 FY26 results** released in late January, where **Net Profit dropped ~57% YoY** to INR 676 crore. This was largely due to one-time impairment charges and the operational headwinds in the US market.

4) Latest Analyst Price Targets (Feb 2026)

The following table summarizes the most recent targets issued by major brokerages in January and February 2026.

Brokerage Firm	Rating	Target Price (INR)	Sentiment
Nomura	Buy	1,770	Bullish
Sharekhan	Buy	1,754	Bullish

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Brokerage Firm	Rating	Target Price (INR)	Sentiment
BOB Capital	Hold	1,394	Neutral
Nuvama	Reduce	1,360	Bearish
Motilal Oswal	Neutral	1,310	Neutral
Morgan Stanley	Underweight	1,292	Bearish
Jefferies	Underperform	1,170	Bearish

Note: Targets are based on reports released post-Q3 FY26 earnings (late Jan 2026) and recent regulatory updates.


Stock Detailed Analysis Report

CIPLA.NS

Current Price: ₹1331.50

Generated: 2026-02-14 10:10

CIPLA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	6.68%	7.88%
Net Income	Yes	No	27.93%	27.96%
ROE	Yes	No	9.52%	11.86%
EPS	Yes	No	27.89%	27.91%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	1.84%	0.06%
Net Income	No	-47.92%	-10.84%
ROE	No	-14.71%	-14.71%
EPS	No	-47.92%	-5.57%

CIPLA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Neutral
RS Score:	44.7/100
:	

== RS RATIOS ==:

1M RS:	0.944 [Neutral]
3M RS:	0.885 [Neutral]
6M RS:	0.844 [Neutral]
1Y RS:	0.896 [Neutral]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✓ Emerging RS:	1M (0.944) > 3M (0.885)
✓ Medium-term Lagging:	6M=0.844, 1Y=0.896 (≤ 1.0)
✗ Performance Improving:	Not improving


Relative Strength Analysis: CIPLA.NS vs ^CNXPHARMA
Classification: Neutral
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



CIPLA.NS - EMA Crossover Summary


EMA 20: 1355.72

EMA 50: 1411.81

EMA 200: 1477.23

Trend Status: **Strong Downtrend**


CIPLA.NS EMA Crossover Analysis



CIPLA.NS - Bollinger Bands Summary

Current Price:	1331.50
Upper Band:	1393.98
Middle Band (SMA 20):	1341.50
Lower Band:	1289.01
%B:	0.4048
Band Width:	0.0783
Status:	Lower Half
Signal:	None
Recent Signal 1:	Buy Signal at 2026-01-21 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2026-01-23 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-27 00:00:00+05:30

CIPLA.NS Bollinger Bands (20, 2) Analysis




CIPLA.NS - Supertrend Summary

Status: DOWNTREND (Sell)

Supertrend Value: 1403.44

Signal Identified On: 2025-10-28


Supertrend Analysis for CIPLA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




CIPLA.NS - MACD Summary

MACD Line:	-29.18
Signal Line:	-35.39
Histogram:	6.21
Trend:	Bullish
Momentum:	Weakening
Signal:	None

CIPLA.NS Price




CIPLA.NS MACD (12, 26, 9)



CIPLA.NS - Volatility Squeeze Summary

BB Width:	0.0783
ATR:	26.9571
Total Signals:	33
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr)
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr)
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
Signal 5:	BB Squeeze + ATR Contraction (Bullish Breakout) at 2026-01-06 00:00:00+05:30 (Pr)


CIPLA.NS - Volatility Squeeze Analysis



CIPLA.NS - RSI-Volume Summary

Current RSI:	34.97
Current Volume:	1236946
Volume MA 20:	2181334
Bullish Divergences:	0
Bearish Divergences:	4
Bearish Div 1:	Date: 2024-10-09 00:00:00+05:30, Price: 1662.74
Bearish Div 2:	Date: 2025-08-25 00:00:00+05:30, Price: 1601.20

CIPLA.NS RSI-Volume Divergence Analysis



CIPLA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status: 44 Signals Detected

:

2026-01-14 [-]: Distribution Day



2026-01-20 [-]: Distribution Day

2026-01-21 [-]: Distribution Day

2026-01-27 [-]: Distribution Day

2026-02-02 [+]: Selling Exhaustion (Bullish Div)

CIPLA.NS - Volume Analysis



CIPLA.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: **No Control**

Recent Trend Score (10-day avg): 0.00

:

Distribution:

No Control: 121


Seller Control: 52

Buyer Control: 48

Buyer Strong Control: 4

Seller Strong Control: 3

CIPLA.NS - Candlestick Classification




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1440.04	1331.5	2026-01-05
1 Day	DOWNTREND (Sell)	1403.44	1331.5	2025-10-28
15 Min	UPTREND (Buy)	1322.81	1331.1	2026-02-13


Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Weakening	No Signal

CIPLA.NS - 1 Week (Candlestick + EMAs)



CIPLA.NS - 1 Day (Candlestick + EMAs)



CIPLA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - CIPLA_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [CIPLA LTD.](#)

Cipla Ltd. [①](#)

NSE: CIPLA | BSE: 500087
Cipla Live Share Price Today, Share Analysis and Chart

Mid-range Performer [①](#) In 4 Starfolio Baskets

1331.50 1.50 (0.11%) [Near 52W Low of ₹1281.70](#)

1.3M NSE+BSE Volume
NSE 13 Feb, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score [①](#) **55.0 /100** Valuation Score [①](#) **36.8 /100** Momentum Score [①](#) **39.3 /100** Analyst Price Target [①](#) **1,456** [FORECASTER](#)

Medium Financial Strength [⑨](#) Mid Valuation [⑨](#) Technically Neutral [⑨](#)

These stocks have average quality, financial and technical momentum, indicating a mid range performer [View Similar](#) Embed DVM [④](#)

SWOT Analysis [④](#)

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank **14** Positive **9** Negative **5** **60.9% Pass in checklist**

PE Valuation Check
Right Now [①](#) Undervalued **28.3%** [1 Year Forward](#) [①](#) Undervalued **19.7%**

INSIGHT Cipla is undervalued at both current PE and future earnings estimates.

Cipla Key Metrics

ROE Ann.% ④ Above industry Median	16.9	Broker Average Target ④ 22.19% upside	1,627	Market Capitalization ④ High in industry	107,556	Price to Book ④ Above Industry Median
--	-------------	--	--------------	---	----------------	--

DVM
Key Metrics
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile X

Trendlyne Snapshot - CIPLA_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) [A](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [CIPLA LTD.](#)

Cipla Ltd. ⓘ

NSE: CIPLA | BSE: 500067

Mid-range Performer ⓘ In 4 Starfolio Baskets

Download real time STOCK REPORT

1331.50 1.50 (0.11%) ↓ Near 52W Low of ₹1281.70

1.3M NSE+BSE Volume

NSE 13 Feb, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes TRADE STOCK

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Cipla - CIPLA - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Cipla has a share price target of Rs 1456, revenue growth forecast of 2.9%, and profit growth estimate of -20.9% for FY26, based on top 37 analyst calls.

Cipla FORECASTER - Analyst Estimates ⓘ

FORECASTER DASHBOARD →

